The Immune Response to Tumors as a Tool toward Immunotherapy
Table 1
Summary of some of the most promising drugs currently under investigation, with their target molecule and more promising diseases of application.
Class of products
Drug name
Target
Malignancies showing promising results
Monoclonal antibodies (mAbs)
Ipilimumab Tremelimumab
CTLA-4
Melanoma*, Non-Hodgkin’s lymphoma, prostate cancer, renal cell cancer
Rituximab
CD20
B-cell lymphoproliferative malignances
Alemtuzumab
CD52
B-CLL
Trastuzumab
HER2/neu
Breast cancer
Cetuximab Panitumumab
EGFR
CRC, head and neck cancer, and others
Bevacizumab
VEGF
CRC, metastatic breast cancer, NSCLC, advanced/metastatic renal cell carcinoma
Conjugated mAbs
Tositumomab Ibritumomab
CD20
B-cell lymphoproliferative malignances
Oncogene inhibitors
Plexxikon
BRAF
Melanoma
Vaccines
Sipuleucel-T
APC presenting prostatic antigens
Prostate cancer
TroVax
APC presenting 5T4 epitope
Advanced CRC, renal cell carcinoma, prostate cancer
HSP90 inhibitors
17-AAG geldanamycin
HSP90
Various cancer
Abbreviations used in the table: APC: antigen presenting Cell, B-CLL: B-cell chronic lymphocytic leukemia, CRC: coloRectal carcinoma, EGFR: epidermal growth factor Receptor, HCC: hepatocellular carcinoma, HSP90: heat shock protein 90, NSCLC: non-small-cell lung carcinoma, VEGF: vascular epidermal growth factor,
*This agent as most of the others may also be used in combination with TAA-based vaccines, cytokines, and chemotherapy.
